TABLE 2.
Baseline clinical characteristics of included study subjects.
| Author, year | Groups | Age (year) | Lumbar spine BMD (g/cm2) | Lumbar spine BMD (T score) | Total hip BMD (g/cm2) | Total hip BMD (g/cm2 or T score) | CTX (ng/ml) | 1,25(OH)2D3 (pg/ml) |
PTH (pg/ml) |
|---|---|---|---|---|---|---|---|---|---|
| Leder, 2015 | Combination | 65.300 ± 8.000 | 0.847 ± 0.130 | — | 0.750 ± 0.068 | — | 0.440 ± 0.170 | — | — |
| Teriparatide | 66.100 ± 7.900 | 0.815 ± 0.109 | — | 0.756 ± 0.072 | — | 0.340 ± 0.150 | — | — | |
| Denosumab | 65.100 ± 6.200 | 0.863 ± 0.096 | — | 0.759 ± 0.102 | — | 0.410 ± 0.220 | — | — | |
| Nakamura, 2017 | Combination | 75.500 ± 1.400 | 0.730 ± 0.108 | — | 0.640 ± 0.108 | — | — | 58.200 ± 17.729 | 28.700 ± 14.019 |
| Denosumab | 75.100 ± 1.800 | 0.799 ± 0.124 | — | 0.620 ± 0.041 | — | — | 56.100 ± 20.191 | 35.700 ± 10.100 | |
| Suzuki, 2018 | Combination | 72.200 ± 2.500 | 0.752 ± 0.124 | — | 0.601 ± 0.082 | — | — | 57.700 ± 25.563 | 28.400 ± 22.625 |
| Denosumab | 74.100 ± 2.000 | 0.800 ± 0.134 | — | 0.631 ± 0.089 | — | — | 54.500 ± 28.622 | 32.600 ± 16.994 | |
| Tsai, 2013 | Combination | 65.900 ± 9.000 | 0.856 ± 0.131 | — | 0.642 ± 0.067 | — | 0.430 ± 0.170 | — | — |
| Teriparatide | 65.500 ± 7.900 | 0.823 ± 0.111 | — | 0.643 ± 0.061 | — | 0.360 ± 0.150 | — | — | |
| Denosumab | 66.300 ± 8.300 | 0.866 ± 0.088 | — | 0.641 ± 0.086 | — | 0.390 ± 0.210 | — | — | |
| Idolazzi, 2016 | Combination | 78.000 ± 5.000 | — | −3.200 ± 0.400 | — | −2.000 ± 0.700 | 0.400 ± 0.180 | — | — |
| Teriparatide | 76.000 ± 5.000 | — | −3.400 ± 0.800 | — | −2.000 ± 0.900 | 0.460 ± 0.200 | — | — | |
| Denosumab | — | — | −3.400 ± 0.400 | — | −1.900 ± 0.800 | 0.470 ± 0.210 | — | — |
Data are mean ± SD; BMD, Bone Mineral Density (areal or volumetric); CTX, Serum β-C-terminal telopeptide of type 1 collagen; PTH, Parathyroid Hormone.